KNSA KINIKSA PHARMACEUTICALS INTL revenue, earnings and financials

For the quarter ended June 30, 2026, KINIKSA PHARMACEUTICALS INTL reported revenue of $244M (up 55.4% from a year earlier), net income of $25.4M and diluted EPS of $0.30; over the last four quarters revenue was $841M and net income $80.7M; for the fiscal year ended December 2025 revenue was $678M, up 60.1% on the year before.

KNSA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $678M, gross profit n/a, operating income $77.2M, net income $59.0M (margin 8.7%), EPS $0.75
• Fiscal year ended Dec 2024: revenue $423M, gross profit n/a, operating income −$45.6M, net income −$43.2M (margin -10.2%), EPS −$0.60
• Fiscal year ended Dec 2023: revenue $270M, gross profit n/a, operating income −$25.2M, net income $14.1M (margin 5.2%), EPS $0.20
• Fiscal year ended Dec 2022: revenue $220M, gross profit n/a, operating income $9.77M, net income $183M (margin 83.3%), EPS $2.60
• Fiscal year ended Dec 2021: revenue $38.5M, gross profit n/a, operating income −$157M, net income −$158M (margin -409.7%), EPS −$2.30

KNSA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $244M (up 55.4% year over year), net income $25.4M, EPS $0.30
• Quarter ended Mar 31, 2026: revenue $214M (up 55.5% year over year), net income $22.6M, EPS $0.27
• Quarter ended Dec 31, 2025 (from the annual report): revenue $202M (up 65.0% year over year), net income $14.2M, EPS $0.18
• Quarter ended Sep 30, 2025: revenue $181M (up 61.2% year over year), net income $18.4M, EPS $0.23
• Quarter ended Jun 30, 2025: revenue $157M (up 44.3% year over year), net income $17.8M, EPS $0.23
• Quarter ended Mar 31, 2025: revenue $138M (up 72.5% year over year), net income $8.54M, EPS $0.11
• Quarter ended Dec 31, 2024 (from the annual report): revenue $123M (up 46.9% year over year), net income −$8.89M, EPS −$0.11
• Quarter ended Sep 30, 2024: revenue $112M (up 67.4% year over year), net income −$12.7M, EPS −$0.18
• Quarter ended Jun 30, 2024: revenue $109M (up 52.0% year over year), net income −$3.91M, EPS −$0.06
• Quarter ended Mar 31, 2024: revenue $79.9M (up 65.2% year over year), net income −$17.7M, EPS −$0.25
• Quarter ended Dec 31, 2023 (from the annual report): revenue $83.4M (up 34.8% year over year), net income $25.2M, EPS $0.37
• Quarter ended Sep 30, 2023: revenue $67.0M (down 32.4% year over year), net income −$13.9M, EPS −$0.20
• Quarter ended Jun 30, 2023: revenue $71.5M (up 165.0% year over year), net income $15.0M, EPS $0.21
• Quarter ended Mar 31, 2023: revenue $48.3M (up 50.2% year over year), net income −$12.3M, EPS −$0.18
• Quarter ended Dec 31, 2022 (from the annual report): revenue $61.9M, net income $4.46M, EPS $0.07
• Quarter ended Sep 30, 2022: revenue $99.1M (up 719.6% year over year), net income $224M, EPS $3.18
• Quarter ended Jun 30, 2022: revenue $27.0M (up 250.1% year over year), net income −$20.0M, EPS −$0.29
• Quarter ended Mar 31, 2022: revenue $32.2M, net income −$25.2M, EPS −$0.36
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$36.3M, EPS −$0.53
• Quarter ended Sep 30, 2021: revenue $12.1M, net income −$30.5M, EPS −$0.44

KNSA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $138M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $25.7M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $13.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $5.81M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$126M, share buybacks n/a

KNSA balance sheet

• Jun 30, 2026: cash $176M, total assets $896M, total liabilities $242M, shareholders' equity $654M
• Mar 31, 2026: cash $190M, total assets $825M, total liabilities $220M, shareholders' equity $606M
• Dec 31, 2025: cash $166M, total assets $764M, total liabilities $196M, shareholders' equity $568M
• Sep 30, 2025: cash $175M, total assets $712M, total liabilities $177M, shareholders' equity $535M
• Jun 30, 2025: cash $192M, total assets $661M, total liabilities $166M, shareholders' equity $495M
• Mar 31, 2025: cash $157M, total assets $599M, total liabilities $142M, shareholders' equity $457M
• Dec 31, 2024: cash $184M, total assets $581M, total liabilities $142M, shareholders' equity $438M
• Sep 30, 2024: cash $97.4M, total assets $555M, total liabilities $118M, shareholders' equity $437M

What is KNSA's revenue?

KINIKSA PHARMACEUTICALS INTL reported $841M of revenue over its last four quarters, through June 30, 2026.

Is KNSA profitable?

Yes. KINIKSA PHARMACEUTICALS INTL earned $80.7M over the last four quarters.

What is KNSA's EPS?

Diluted earnings per share over the last four quarters were $0.98; $0.30 in the latest quarter.

KNSA ownership and insider trades · All stocks